Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Colorectal Cancer Policy Will Not Limit Current Off-Label Coverage, CMS Says

Executive Summary

The Centers for Medicare & Medicaid Services' national coverage determination for four colorectal cancer therapies will not limit coverage of other off-label indications, the agency said

You may also be interested in...



Medicare To Use Evidence Development For Off-Label Drug Use? CMS Guidance Unclear

CMS’ guidance on its “coverage with evidence development” policy for Medicare Part B does not elaborate on the scope of its application to off label drug use, only stating the agency could apply CED to drugs that have received FDA approval for at least one indication.

A Closer Look: Colorectal Cancer National Coverage Decision After One Year

Nearly a year after CMS finalized a contentious national coverage decision (NCD) on certain off-label uses of colorectal cancer drugs, five out of nine eligible clinical trials have yet to open for patient enrollment, according to the National Cancer Institute (NCI)

A Closer Look: Colorectal Cancer National Coverage Decision After One Year

Nearly a year after CMS finalized a contentious national coverage decision (NCD) on certain off-label uses of colorectal cancer drugs, five out of nine eligible clinical trials have yet to open for patient enrollment, according to the National Cancer Institute (NCI)

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS045330

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel